header-22.jpg
Home

APCRCQgroupPhoto

About Us

More About Us

The Australian Prostate Cancer Research Centre–Queensland is a disease-specific, multidisciplinary, highly collaborative prostate cancer research centre focusing on the development of new therapeutics and biomarkers for prostate cancer and their translation into the clinical setting. Located within the state-of-the-art Translational Research Institute in Brisbane, the APCRC–Q forms a hub for prostate cancer research in Queensland.

More >

Support the APCRC-Q Team during MOvember!

DONATE

MOvember

Globally, more than 1.4M men are diagnosed with prostate cancer each year.

Movember is working to halve the number of deaths from prostate cancer by 2030, and with our research, we help them get there! Thus, please donate to support prostate cancer research for all the dads, brothers, sons and mates in our lives!

APCRC-Q News

Sep 06, 2021 PA Giving Day PA Prostate Team Fundraising a Great Success

The APCRC-Q PA Prostate Cancer team had a engaging 2nd Sept 2021, raising funds for the PA Giving Day We’re all 4 the Heroes campaign. More >

Dec 31, 2020 APCRC-Q Founder and Executive Director Professor Colleen Nelson Celebrated in Australia Day 2021 Honours

Professor Colleen Nelson has been appointed a Member of the Order of Australia, for significant service to medical research, particularly prostate cancer, and to health organisations, in the 2021 Australia Day Honours. More >

Nov 10, 2020 New prostate cancer therapeutics being developed by APCRC-Q researchers could also fight COVID-19

Therapies being developed by the Centre's Dr Lisa Philp and Professor Colleen Nelson for prostate cancer, could also be used to fight the worst symptoms of COVID-19. More >

Feb 13, 2020 APCRC-Q Celebrates our 10 Year Anniversary

This month APCRC-Q turned 10. More >

Feb 10, 2020 APCRC-Q researchers provide commentary on recent cancer publications

A suite of 23 articles recently published in Nature and its affiliated journals detailed the results of research conducted by the Pan-Cancer Analysis of Whole Genomes Consortium. More >